A5056101772- Ocular Oncology and Treatments
- Immunotherapy and Immune Responses
- Ubiquitin and proteasome pathways
- Retinal Development and Disorders
- Cutaneous Melanoma Detection and Management
- Nanoplatforms for cancer theranostics
- Cancer-related Molecular Pathways
- Genomics and Chromatin Dynamics
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
University of Genoa
2023-2025
University Hospital of Zurich
2025
Ospedale Policlinico San Martino
2021-2023
Tebentafusp is the first T-cell receptor-based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T-cells toward gp100-expressing target cells, frequently inducing skin-related early adverse events. This study investigated immunological and cellular responses using single-cell spatial analysis of skin biopsies from metastatic melanoma treated tebentafusp. 81.8% developed acute cutaneous events, which...
<title>Abstract</title> Uveal melanoma (UM) is the most common intraocular tumor, and despite being rare, it accounts for nearly 13% of melanoma-related deaths. Indeed, patients with metastatic disease have typically a survival rate less than one year, little improvement over past few decades. Although <italic>TP53</italic> mutations are uncommon in UM, recent findings highlight dysfunctional p53 pathway this cancer. Given its crucial role mediating DNA damage responses, we analyzed protein...
Uveal melanoma (UM) is characterized by relatively few, highly incident molecular alterations and their association with metastatic risk deeply understood. Nevertheless, this knowledge has so far not led to innovate therapies for the successful treatment of UM metastases or adjuvant therapy, leaving survival after diagnosis almost unaltered in decades. The driver mutations UM, mainly G-protein genes GNAQ GNA11, activate MAP-kinase pathway as well YAP/TAZ pathway. At present, there are no...
The metastatic risk of uveal melanoma (UM) is defined by a limited number molecular lesions, somatic mutations (SF3B1 and BAP1), copy alterations (CNA): monosomy chromosome 3 (M3), chr8q gain (8q), chr6p (6p), yet the sequence events not clear. We analyzed data from three datasets (TCGA-UVM, GSE27831, GSE51880) with information regarding M3, 8q, 6p, SF3B1, BAP1 status. confirm that are always associated M3 in high-risk patients. All other features (6p, SF3B1 mutation) were present...